Why “Medical Necessity” Is the #1 Audit Vulnerability for Skin Substitutes

Across Medicare audits, denials of skin substitute (CTP) claims most often hinge on a single issue: medical necessity. Even when products are FDA-cleared and correctly billed, auditors routinely find that the clinical record fails to demonstrate why a CTP was reasonable and necessary for that specific patient, wound, and moment in care. 

Key takeaways 

• Medical necessity drives many CTP denials: Auditors deny claims when the record fails to justify why a skin substitute was reasonable and necessary, even if the product itself is covered. 

• Product indications are not enough: FDA clearance and manufacturer labeling do not establish Medicare medical necessity for an individual patient. 

• Documentation determines outcomes: Auditors judge what is written, not what was intended—making clear, patient-specific wound documentation essential for every CTP application. 

In wound care, few phrases carry as much weight—or as much risk—as medical necessity. CMS defines it as services that are reasonable and necessary for the diagnosis or treatment of illness or injury and that meet accepted standards of medical practice.¹ For cellular and/or tissue-based products (CTPs), this standard is where audits frequently unravel. 

The problem in this concept is not a lack evidence or clinical value. The problem is that medical necessity must be proven in the medical record, not assumed based on product labeling, FDA status, or clinician intent.^2-4 

Why Medical Necessity Dominates CTP Audit Findings

Medicare contractors will deny claims when the documentation does not support that services were reasonable and necessary—even if the service itself is covered in theory.^1,2 In practice, CTP claims are vulnerable because they are high-cost, highly variable, and dependent on longitudinal wound documentation. 

Local Coverage Determinations (LCDs) governing skin substitute use consistently emphasize that coverage depends on patient selection, wound characteristics, prior care, and response to treatment—all of which must be clearly documented.³ When any part of that story is incomplete, auditors may default to denial for lack of medical necessity.^3,4 

Common Failure Points in CTP Documentation

1. Inadequate demonstration of chronicity and prior standard care 

2. Missing or inconsistent objective wound data 

3. Lack of a clear ‘why now?’ rationale 

4. Frequency and duration mismatches 

Over-Reliance on Product Indications: A Critical Misstep

One of the most common misconceptions in wound care audits is that FDA clearance or manufacturer indications equal medical necessity. They do not. 

CMS and its contractors repeatedly state that coverage decisions are based on Medicare law and policy—not FDA labeling or marketing materials.^1,2 Product indications may establish that a CTP can be used for certain wounds, but they do not prove that it should be used for this patient, at this time, in this way.^3,4 

Audit findings frequently cite records that rely heavily on product names and indications while lacking individualized clinical assessment. This creates a disconnect between what was done and why it was medically necessary. 

Documentation vs Clinical Reality: Where Audits are Lost

Clinicians may feel confident that a CTP was appropriate based on experience and patient outcomes. Auditors, however, do not infer intent or fill in gaps. They evaluate only what is documented.^2,4 

CMS policy is clear: medical necessity must be supported by contemporaneous documentation in the medical record.¹ Late clarifications, templated language without patient-specific detail, or retrospective narratives created during appeal carry little weight^.2,4 

This disconnect explains why well-meaning, clinically sound care still results in denials. The issue is not always clinical judgment—it is the failure to translate that judgment into a clear, auditable record. 

The Evergreen Lesson for Wound Care Teams

Medical necessity remains the top audit vulnerability for CTPs because it is subjective, documentation-heavy, and scrutinized at multiple levels of review.^2-5 While products, prices, and policies may change, the core expectation does not: the record must clearly show why advanced therapy was required and how it aligned with Medicare coverage criteria. 

For wound care professionals, the most durable audit defense is not choosing the “right” product—it is consistently documenting the clinical reasoning that made advanced therapy necessary in the first place.^1-5 

References 

1. Centers for Medicare & Medicaid Services. Medicare Program Integrity Manual. Chapter 13: Local Coverage Determinations. CMS. Accessed February 9, 2026. https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/pim83c13.pdf 

2. Centers for Medicare & Medicaid Services. Medicare Program Integrity Manual. Chapter 3: Verifying Potential Errors and Taking Corrective Actions. CMS. Accessed February 9, 2026. https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/pim83c03.pdf 

3. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determinations (LCDs)—Skin Substitute Grafts/CTPs. CMS. Accessed February 9, 2026. https://www.cms.gov/medicare-coverage-database/ 

4. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. Chapter 23: Fee Schedule Administration and Medical Review. CMS. Accessed February 9, 2026. https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c23.pdf 

5. Fife CE, Carter MJ, Walker D, Thomson B. Wound care outcomes and associated cost among patients treated in U.S. outpatient wound centers. Wound Repair Regen. 2012;20(2):183-193. doi:10.1111/j.1524-475X.2012.00765.x